Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis PDF Print E-mail
Saturday, 02 October 2010 23:27
Marco Matucci-Cerinic, Christopher P Denton, Daniel E Furst, Maureen D Mayes, Vivien M Hsu, Patrick Carpentier, Fredrick M Wigley, Carol M Black, Barri J Fessler, Peter A Merkel, Janet E Pope, Nadera J Sweiss, Mittie K Doyle, Bernhard Hellmich, Thomas A Medsger Jr, Adele Morganti, Fabrice Kramer, Joseph H Korn, James R Seibold
Ann Rheum Dis published online August 30, 2010
doi: 10.1136/ard.2010.130658

Objectives
Ischaemic digital ulcers (DUs) are common in patients with systemic sclerosis (SSc) and are a cause of disease-related morbidity. In an earlier trial, treatment with bosentan, an oral endothelin receptor antagonist, reduced the occurrence of new DUs by 48%. The present study (RAPIDS-2, for ‘RAndomized, double-blind, Placebocontrolled study with bosentan on healing and prevention of Ischemic Digital ulcers in patients with systemic Sclerosis’) was conducted to more fully evaluate the effects of bosentan treatment on DUs associated with SSc.

Methods
This double-blind, placebo-controlled trial conducted at 41 centres in Europe and North America randomised 188 patients with SSc with at least 1 active DU (‘cardinal ulcer’) to bosentan 62.5 mg twice daily for 4 weeks and 125 mg twice daily thereafter for 20 weeks (n=98) or matching placebo (n=90; total 24 weeks). The two primary end points were the number of new DUs and the time to healing of the cardinal ulcer. Secondary end points included pain, disability and safety.

Results
Over 24 weeks, bosentan treatment was associated with a 30% reduction in the number of new DUs compared with placebo (mean±standard error: 1.9±0.2 vs 2.7±0.3 new ulcers; p=0.04). This effect was greater in patients who entered the trial with more DUs. There was no difference between treatments in healing rate of the cardinal ulcer or secondary end points of pain and disability. Peripheral oedema and elevated aminotransferases were associated with bosentan treatment.

Conclusions
Bosentan treatment reduced the occurrence of new DUs in patients with SSc but had no effect on DU healing. Bosentan was well tolerated and may be a useful adjunct in the management of patients with SSc with recurrent DUs.

Login to download your own copy of the full and original article from the link provided below

 
More articles :

» Rare Diseases Day

Febuary 28th, 2010 was Rare Diseases Day, and it was marked with a variety of events and activities all over the world - as well as with plenty of citizen media and online participation. The goal was to raise awareness about so-called. These are...

» Immunosuppressive Medications During Pregnancy and Lactation In Women with Autoimmune Diseases

Amy B Elliott & Eliza F Chakravarty10.2217/WHE.10.24 © 2010 Future Medicine LtdWomen's Health (2010) 6(3), 431–442Most autoimmune diseases predominantly affect females. Many of these diseases occur in women who have the potential to become...

» Scleroderma and Lupus Health Study Claims No Environmental Link To Disease

The Massachusetts Department of Public Health (DPH) has released the results of an investigation into the occurrence of and lupus, two rare chronic diseases, in South Boston. The investigation found that the prevalence of scleroderma was indeed...

» Prevalence and Correlates of Sleep Disturbance in Systemic Sclerosis

Tracy Frech, Ron D. Hays, Paul Maranian, Philip J. Clements, Daniel E. Furst and Dinesh KhannaObjective:Rheumatologic disorders are associated with sleep disturbances. This study examines sleep disturbance correlates in patients with...

» Moves Toward Personalized Medicine for Scleroderma

researchers have received two five-year grants totaling $953,000 from the National Institutes of Health's (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases to study , an autoimmune disease for which there currently is no...

» Vascular Complications of Systemic Sclerosis during Pregnancy

Eliza F. Chakravarty, MD MSSystemic sclerosis (SSc) is a chronic autoimmune disorder characterized by progressive fibrosis of the skin and visceral tissues as well as a non-inflammatory vasculopathy. Vascular disease in systemic sclerosis is a major...